5:16 PM
Apr 05, 2019
 |  BioCentury  |  Finance

Room to rally in 2Q

Biotech out-performance could continue in 2Q if M&A rally keeps up

Strong small and mid-cap performance coupled with robust M&A has brought the sector back from 4Q18 correction territory, and chances are good for the momentum to continue given the ample capital ready to be recycled back into biotech, and lack of growth opportunities elsewhere. Buysiders are optimistic the sector will keep up with if not outpace the broader markets -- particularly if the M&A rally continues.

The first week of the new quarter has already seen a spate of new deals, including an M&A transaction and an IPO from companies working on non-alcoholic steatohepatitis (NASH) programs.

On April 1, Novartis AG acquired IFM Tre Inc. and its trio of NLRP3 antagonists, which are in development for a range of inflammatory diseases, among them NASH.

NGM Biopharmaceuticals Inc. raised $106.7 million in an IPO on April 4, making it the second NASH company to list on NASDAQ in two weeks; Genfit S.A. raised $125 million through a dual listing on March 27.

“We need to see a few more deals just like in Q1. Everything else is almost secondary.”

Sven Borho, OrbiMed

But M&A is the major theme. “The most important ingredient for Q2 biotech outperformance is M&A. We need to see a few more deals just like in Q1. Everything else is almost secondary,” OrbiMed’s Sven Bohro told BioCentury.

Bristol-Myers Squibb Co. kicked off the year with plans to acquire Celgene Corp. in a cash and stock deal valued at more than $70 billion -- the largest-ever pure biotech takeout -- and the first quarter saw three additional deals valued at over $1 billion (see “Bristol-Myers’ Next Phoenix Act?”).

Upfront payments alone across 14 disclosed deals in 1Q19 will provide investors with nearly $50 billion in dry powder, a significant bump up from the $30.3 billion in upfront cash freed up via 11 disclosed deals in 1Q18 and the $13.9 billion in upfront payments from 13 deals in 4Q18 (see "Table: Announced M&A").

The March 21 announcement from Biogen Inc. and Eisai Co. Ltd. to terminate Phase III trials of Biogen’s aducanumab for Alzheimer’s disease leaves the big biotech in need of new growth drivers and puts the spotlight back on dwindling big cap pipelines, which could keep M&A at its current clip (see “Big Caps Under Pressure”).

“At the end of the day, small innovative biotech is where the next great drugs are coming from, so from that perspective, innovation is only going to get more and more valuable,” EcoR1’s Oleg Nodelman told BioCentury.

In the near term, most buysiders are ignoring macroeconomic risks such as Brexit, the U.S.'s tensions with North Korea, its trade war with China and its rhetoric on drug pricing. Buysiders do, however, expect more volatility as the election year approaches.

Meanwhile, investors with a bent towards China will be watching the next Hong Kong stock exchange listings closely, with an expectation of more reasonable valuations than the first crop.

The expanded remit of the Committee on Foreign Investment in the United States (CFIUS) is also top of mind for Chinese investors and could be a cloud over foreign investment in private U.S. biotechs. It is unlikely to affect public companies.

Table: Announced M&A

1Q19 started strong on the deal front, with the Jan. 3 announcement that Bristol-Myers Squibb Co. (NYSE:BMY) would acquire Celgene Corp. (NASDAQ:CELG) in a cash and stock deal valued at over $70 billion up front, plus a tradable contingent value right (CVR) worth up to $9 per...

Read the full 2913 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >